Home / News / BioBlast® / Biosimilar Deals 2019

EXPLORE OUR

Biosimilars Deals 2019

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast updates below.

Mylan and Pfizer announce deal to form NewCo

Mylan and Pfizer announce deal under which Mylan and UpJohn (a division of Pfizer) will merge to form NewCo (name to be announced).  Under the deal, Pfizer shareholders will own 57% of the combined company, and Mylan shareholders 43%.  Mylan CEO Heather Bresch will retire as part of the deal, and the new CEO will be Michael Goettler, current Upjohn group President.  Mylan notes its biosimilars as bringing key growth to NewCo, including trastuzumab (Ogivri), bevacizumab (the India-approved and launched Abevmy), pegfilgrastim (Fulphila), and insulin glargine (Semglee, approved and launched in EU and elsewhere), and the pipeline biosimilars abatacept and aflibercept.  Read more.

BioBlast® Editor and Contributing Author

Naomi Pearce & Emily Dwyer

Naomi Pearce & Emily Dwyer

Editor: Naomi Pearce, Executive Lawyer, Patent Attorney & Trade Mark Attorney
Contributing Author: Emily Dwyer, Graduate Lawyer, Trainee Trade Mark Attorney

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.